Repatha Starting Dose After Cardiac Catheterization
For adults with established cardiovascular disease (including post-cardiac catheterization), initiate Repatha (evolocumab) at either 140 mg subcutaneously every 2 weeks OR 420 mg subcutaneously once monthly. 1
Dosing Algorithm
The FDA-approved dosing for patients with established ASCVD provides two equivalent options 1:
- 140 mg SC every 2 weeks (preferred for most patients due to simpler administration)
- 420 mg SC once monthly (requires either the on-body infuser OR three consecutive 140 mg injections within 30 minutes)
Both regimens produce comparable LDL-C reductions of approximately 58-64% when added to statin therapy 2.
Clinical Context Post-Cardiac Catheterization
Timing of initiation matters for optimal outcomes. Recent real-world evidence demonstrates that:
- Ultra-early initiation (in the catheterization laboratory immediately after angiography) achieves 66.4% dual LDL-C target attainment (<1.4 mmol/L and ≥50% reduction) at 4 weeks 3
- Single-dose 140 mg evolocumab during the peri-PCI period resulted in 97.7% of patients achieving LDL-C <55 mg/dL at 1-3 weeks 4
- Early initiation (within 48 hours) in high-risk ACS patients reduced 3-month MACE by approximately 60% (HR 0.42) 5
The LDL-lowering effect can be measured as early as 4 weeks after initiation 1, though substantial reductions occur within 1-3 weeks 4.
Administration Specifics
- Inject subcutaneously in the abdomen, thigh, or upper arm
- Rotate injection sites with each administration
- For latex-sensitive patients: prescribe the presentation without natural rubber latex, as some formulations contain dry natural rubber in the needle cover 1
Important Caveats
Do not delay initiation waiting for "optimal" statin titration. The 2022 ACC Expert Consensus supports adding evolocumab to maximally tolerated statin therapy in adults with ASCVD 2. Post-cardiac catheterization patients have established ASCVD by definition, making them appropriate candidates for immediate PCSK9 inhibitor therapy.
Monitor for hypersensitivity reactions, particularly angioedema, though these are rare. If serious hypersensitivity occurs, discontinue immediately 1.
No dose adjustment is needed based on renal or hepatic function, and the safety profile in post-ACS patients shows no increase in adverse events compared to standard therapy 6, 5.
The evidence strongly supports that earlier is better in the post-catheterization setting, with multiple studies demonstrating safety and enhanced efficacy when initiated during the index hospitalization 4, 6, 3, 5.